Saturday, 31 October 2026European Markets

MEMSCAP REGPT Stock Over 27% Up In The Last 21 Sessions

Loading stream...

(vianews) - shares of memscap regpt (cac 40: mems.pa) rose by a staggering 27.42% in 21 sessions from €3.1 to €3.95 at 17:05 est on monday, after four successive sessions in a row of losses. cac 40 is dropping 0.91% to €7,204.79, after two successive sessions in a row of gains.

memscap regpt's last close was €3.90, 2.5% under its 52-week high of €4.00.

about memscap regpt

memscap, s.a. provides micro-electro-mechanical systems (mems) based solutions for aerospace and defense, optical communications, medical and biomedical, and it/consumer markets worldwide. the company offers pressure sensors, pressure transducers, and pressure switches for various applications, such as air data computers, cabin pressure, engine control, altimeters, barometers, cockpit instruments, and air data test sets. it also provides gold coated and titanium-based pressure transducers, plastic domes, line-sets, and related accessories; and magnetic switches/relays, as well as supplies implantable pressure sensors for spinal pressure monitoring, abdominal aortic aneurism, etc. in addition, the company supplies optical mems chips for variable optical attenuators in optical telecommunication markets; and provides the multi-user mems processes (mumps) comprising polymumps, soimumps, and piezomumps, as well as mumps-plus and post processing services. further, it offers custom products, including wafers, mems dies, and wafer level packaged devices; and manufacturing services, as well as prototyping services. the company sells its products and services to fortune 500 companies, high-technology industries, research institutes, and universities. memscap, s.a. was founded in 1997 and is headquartered in crolles, france.

more news about memscap regpt (mems.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com